相关实验视频
Updated: Jul 13, 2025

08:05
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
40.3K
在个性化医疗时代的喘现象
Victor Gonzalez-Uribe1,2, Sergio J Romero-Tapia3, Jose A Castro-Rodriguez4
1Alergia e Inmunología Clínica, Hospital Infantil de México Federico Gómez, Ciudad de Mexico 06720, Mexico.
Journal of clinical medicine
|October 14, 2023
概括
喘是一种全球性呼吸道疾病,是复杂而异质的. 了解其免疫内型是开发个性化药物和针对严重喘的向治疗的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 个性化医疗是个性化的医疗.
背景情况:
- 全球有3亿人患喘,导致严重的发病率,死亡率和经济负担.
- 最近的研究强调了喘异质性的免疫学基础.
- 目前的理解认为喘是一种复杂的疾病,具有多种不同的潜在机制.
研究的目的:
- 审查喘病原性中的关键免疫机制.
- 为了将免疫学内型与喘表型相关联.
- 讨论严重喘的个性化治疗策略.
主要方法:
- 审查最近的临床和实验室研究进展.
- 导致喘的免疫因素的综述.
- 对个性化医学的内型分类的分析.
主要成果:
- 喘是一种异质性疾病,由不同的免疫路径驱动.
- 内型鉴定对于准确的患者简介至关重要.
- 针对性生物制剂对特定的免疫路径有很大的前景.
结论:
- 个性化医疗需要了解喘内型.
- 根据特定的免疫机制量身定制治疗方法可以改善治疗结果.
- 对免疫内型的进一步研究将促进严重喘管理.
相关概念视频
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Asthma: Pathogenesis and Management
421
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
421
Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
313
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
313
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324

